DRUG DEVELOPMENT PIPELINE

Back to the Drug Development Pipeline

Vancomycin Inhalation Powder (AeroVanc™)

Phase Two

Phase Two

Therapeutic Approach

Anti-Infective

Vancomycin inhalation powder (AeroVanc™) is an inhaled dry powder version of the antibiotic vancomycin for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) airway infection in people with CF.

Status

Results from a U.S. multicenter Phase 2 trial showed that study participants who received AeroVanc™ experienced a significant reduction in MRSA density in their sputum compared with those given a placebo. 

Sponsor

This program is sponsored by Savara Pharmaceuticals and partially funded by Cystic Fibrosis Foundation Therapeutics. It is being conducted within CFFT's Therapeutics Development Network.

Contact us about Vancomycin Inhalation Powder (AeroVanc™) >